Featured Research

from universities, journals, and other organizations

Experimental Drug Used To Treat Recurrent Ovarian Cancer Shows Promising Results

Date:
February 23, 2004
Source:
Yale University
Summary:
Yale researchers have reported promising preliminary results of a Phase Ib/IIa study in women with recurrent ovarian cancer using phenoxodiol, an experimental anti-cancer drug that could kill cancer cells and increase effectiveness of standard chemotherapy.

Yale researchers have reported promising preliminary results of a Phase Ib/IIa study in women with recurrent ovarian cancer using phenoxodiol, an experimental anti-cancer drug that could kill cancer cells and increase effectiveness of standard chemotherapy.

Related Articles


The data were presented by David O'Malley, M.D., instructor, Department of Obstetrics, Gynecology & Reproductive Sciences, at the 35th Annual Meeting of the Society of Gynecologic Oncologists in San Diego, California on February 8. The researchers found no toxicity, 25 percent response and synergy with chemotherapy. The main purpose of the study was to determine the dose of phenoxodiol to be used in combination with other anti-cancer drugs.

While phenoxodiol has the ability to stop ovarian cancer growth in animals in its own right, Yale researchers and the drug's developer, Marshall Edwards, Inc., are developing the drug in late-stage ovarian cancer as a chemo-sensitizer, restoring the sensitivity of the cancer cells to standard chemotherapeutic drugs.

"Patients received phenoxodiol twice a week, which is how we believe it will be used in combinational therapy," said principal investigator Thomas Rutherford, M.D., associate professor of gynecology, Department of Obstetrics, Gynecology & Reproductive Sciences. "We did expect to see a major anti-tumor effect when used at this dose, with an apparent 25 percent stability rate in unresponsive cancers. These results gave us confidence in the potential use of phenoxodiol for the treatment of ovarian cancer. We are highly encouraged by the outcome."

The data reflected outcomes from the first 20 of 40 patients enrolled in the study with late-stage ovarian cancer that had become unresponsive to standard chemotherapy. Of the 20 patients who started the course of treatment, 13 were able to finish a three-month program without disease progression. Five of these patients were evaluated to have disease stabilization; all these patients later progressed.

In a follow up of the study, eight of nine patients who were treated with paclitaxel-standard chemotherapy-following completion of the phenoxodiol trial showed a positive serologic response to paclitaxel therapy. Four of these patients had previously been defined as paclitaxel resistant.

"This is a preliminary observation only, but one that we find highly encouraging because it confirms in humans what we saw in the laboratory -- that phenoxodiol is a powerful chemo-sensitizer," said Gil Mor, M.D., PhD, associate professor and a co-investigator in the study.


Story Source:

The above story is based on materials provided by Yale University. Note: Materials may be edited for content and length.


Cite This Page:

Yale University. "Experimental Drug Used To Treat Recurrent Ovarian Cancer Shows Promising Results." ScienceDaily. ScienceDaily, 23 February 2004. <www.sciencedaily.com/releases/2004/02/040223074256.htm>.
Yale University. (2004, February 23). Experimental Drug Used To Treat Recurrent Ovarian Cancer Shows Promising Results. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2004/02/040223074256.htm
Yale University. "Experimental Drug Used To Treat Recurrent Ovarian Cancer Shows Promising Results." ScienceDaily. www.sciencedaily.com/releases/2004/02/040223074256.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
WHO Says Male Ebola Survivors Should Abstain From Sex

WHO Says Male Ebola Survivors Should Abstain From Sex

Newsy (Nov. 28, 2014) — WHO cites four studies that say Ebola can still be detected in semen up to 82 days after the onset of symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins